Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
948 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01852292 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | terminated | Phase 2 | 157 | Novartis PharmaceuticalsINDUSTRY | 18 | Jul 24, 2018 | clinicaltrials |
| NCT02720510 | A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)(PANORAMA4) | terminated | Phase 2 | 6 | Novartis PharmaceuticalsINDUSTRY |
| 1 |
| Jul 24, 2018 |
| clinicaltrials |
| NCT01582061 | An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.(SEASCAPE) | completed | Phase 3 | 104 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 19, 2018 | clinicaltrials |
| NCT02678260 | Phase I Study of PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 8, 2018 | clinicaltrials |
| NCT01870726 | Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 43 | Novartis PharmaceuticalsINDUSTRY | 5 | May 30, 2018 | clinicaltrials |
| NCT01200589 | Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy(HOMER) | terminated | Phase 3 | 438 | Novartis PharmaceuticalsINDUSTRY | 16 | May 16, 2018 | clinicaltrials |
| NCT01137682 | Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly(PAOLA) | completed | Phase 3 | 198 | Novartis PharmaceuticalsINDUSTRY | 18 | Apr 5, 2018 | clinicaltrials |
| NCT03081234 | Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer(EarLEE-2) | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 15, 2018 | clinicaltrials |
| NCT00867113 | Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 91 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 14, 2018 | clinicaltrials |
| NCT00790816 | Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents | completed | Phase 1 | 500 | Novartis PharmaceuticalsINDUSTRY | 5 | Feb 28, 2018 | clinicaltrials |
| NCT01691807 | Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 30 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 28, 2018 | clinicaltrials |
| NCT02137889 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients(VAY736Y) | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 2 | Feb 28, 2018 | clinicaltrials |
| NCT01083602 | Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma(MACS1271) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2017 | clinicaltrials |
| NCT01376115 | Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg | completed | — | 343 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 1, 2017 | clinicaltrials |
| NCT02108951 | Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.(ENESTswift) | terminated | Phase 3 | 20 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 27, 2017 | clinicaltrials |
| NCT00063609 | The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy | completed | Phase 4 | 200 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 13, 2017 | clinicaltrials |
| NCT00086268 | Non-small Cell Lung Cancer Study US75 (Z-PACT)(ZPACT) | completed | Phase 3 | 250 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 13, 2017 | clinicaltrials |
| NCT00535418 | Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers | completed | Phase 2 / Phase 3 | 35 | Novartis PharmaceuticalsINDUSTRY | 0 | Sep 5, 2017 | clinicaltrials |
| NCT01708174 | A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) | completed | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 13 | Aug 11, 2017 | clinicaltrials |
| NCT01514448 | Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib | completed | Phase 4 | 29 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00790036 | Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy(PILLAR2) | completed | Phase 3 | 742 | Novartis PharmaceuticalsINDUSTRY | 34 | Jul 12, 2017 | clinicaltrials |
| NCT00375752 | Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer(FEMZONE) | terminated | Phase 4 | 168 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00633295 | Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 22, 2017 | clinicaltrials |
| NCT01685060 | LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib | completed | Phase 2 | 140 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 19, 2017 | clinicaltrials |
| NCT01440374 | A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia(ASPIRE) | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 5, 2017 | clinicaltrials |
| NCT00375648 | Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer(TRAPEZE) | completed | Phase 3 | 61 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 2, 2017 | clinicaltrials |
| NCT00171964 | Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions | completed | Phase 4 | 75 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 1, 2017 | clinicaltrials |
| NCT01316458 | Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy | completed | Phase 2 | 51 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00219271 | Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer | completed | Phase 4 | 60 | Novartis PharmaceuticalsINDUSTRY | 1 | May 31, 2017 | clinicaltrials |
| NCT01013740 | Lapatinib in Combination With Vinorelbine(VITAL) | completed | Phase 2 | 112 | Novartis PharmaceuticalsINDUSTRY | 10 | May 31, 2017 | clinicaltrials |
| NCT01172548 | Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)(INV555) | completed | Phase 2 | 132 | Novartis PharmaceuticalsINDUSTRY | 12 | May 31, 2017 | clinicaltrials |
| NCT00670553 | A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer | completed | Phase 1 | 7 | Novartis PharmaceuticalsINDUSTRY | 1 | May 17, 2017 | clinicaltrials |
| NCT03070691 | Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) | withdrawn | Phase 2 / Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 10 | May 5, 2017 | clinicaltrials |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | terminated | Phase 2 | 65 | Novartis PharmaceuticalsINDUSTRY | 3 | May 3, 2017 | clinicaltrials |
| NCT00863655 | Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole(BOLERO-2) | completed | Phase 3 | 724 | Novartis PharmaceuticalsINDUSTRY | 24 | May 2, 2017 | clinicaltrials |
| NCT01605981 | Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.(MACS1881) | withdrawn | Phase 4 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 20, 2017 | clinicaltrials |
| NCT01613677 | Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 20, 2017 | clinicaltrials |
| NCT01064310 | Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer(PISCES) | completed | Phase 3 | 169 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 17, 2017 | clinicaltrials |
| NCT02240212 | Study of Afuresertib Combined With Paclitaxel in Gastric Cancer | completed | Phase 1 | 29 | Novartis PharmaceuticalsINDUSTRY | 2 | Apr 11, 2017 | clinicaltrials |
| NCT01007942 | Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer(BOLERO-3) | completed | Phase 3 | 569 | Novartis PharmaceuticalsINDUSTRY | 21 | Apr 5, 2017 | clinicaltrials |
| NCT00332969 | Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma | completed | Phase 2 | 25 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00719264 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | completed | Phase 2 | 365 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 20, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT01831726 | Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib(SIGNATURE) | completed | Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT01572727 | A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation(BELLE-4) | completed | Phase 2 / Phase 3 | 416 | Novartis PharmaceuticalsINDUSTRY | 22 | Mar 9, 2017 | clinicaltrials |
| NCT00052013 | Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 | completed | Phase 2 | 11 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00056446 | Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer | completed | Phase 3 | 855 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 6, 2017 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials